Amicus Therapeutics Repays Blackstone Debt, Terminates Credit Agreement Following BioMarin Merger
summarizeSummary
Amicus Therapeutics has fully repaid and terminated its 2023 credit agreement with Blackstone, a significant financial cleanup directly following the completion of its merger with BioMarin Pharmaceutical Inc. This move, which incurred no exit fees, streamlines Amicus's capital structure as it becomes a wholly-owned subsidiary of BioMarin. The repayment confirms a smooth financial transition post-merger, removing a key liability. Investors will now monitor the integration process and any further financial disclosures from the combined entity.
At the time of this announcement, FOLD was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.